Showing results (1-10 of 1,296) with videos related to

Sort By:
Pageof 130
British Journal of Clinical Pharmacology|May 28, 2025
Approaches to repurposing reverse transcriptase antivirals in cancerRichard Head, Saiful Islam, Jennifer H Martin
Pharmacology Research & Perspectives|July 27, 2025
A Unified Explanation for Drug Repurposing and Pharmacological Pleiotropy Based on Classical and Statistical ThermodynamicsRichard Head, Saiful Islam, Jennifer H Martin
Pharmaceuticals (Basel, Switzerland)|October 27, 2022
Combined <i>In Silico</i> and <i>In Vitro</i> Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer CellsSaiful Islam, Theodosia Teo, Malika Kumarasiri, et al.
Cancers|February 25, 2023
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase InhibitionSaiful Islam, Muhammed H Rahaman, Mingfeng Yu, et al.
British Journal of Clinical Pharmacology|September 22, 2020
A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19Jennifer H Martin, Richard Head
British Journal of Clinical Pharmacology|June 30, 2021
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential targetSaiful Islam, Shudong Wang, Nikola Bowden, et al.
Pharmacology Research & Perspectives|June 25, 2020
Buying time: Drug repurposing to treat the host in COVID-19HJennifer H Martin, Julian Clark, Richard Head
British Journal of Clinical Pharmacology|September 17, 2015
Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastomaDayle Rundle-Thiele, Richard Head, Leah Cosgrove, et al.
Molecular Therapy. Oncology|January 13, 2025
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancerBayley Matthews, Michelle Wong-Brown, Dongli Liu, et al.
Pharmacology Research & Perspectives|January 14, 2022
"LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategyBevyn Jarrott, Richard Head, Kirsty G Pringle, et al.
Pageof 130